Have a personal or library account? Click to login
Does volume change of the spleen correlate with the therapy response in uveal melanoma patients with liver metastases undergoing hepatic artery infusion chemotherapy? Cover

Does volume change of the spleen correlate with the therapy response in uveal melanoma patients with liver metastases undergoing hepatic artery infusion chemotherapy?

Open Access
|Sep 2025

References

  1. Carvajal RD, Schwartz GK, Tezel T, Marr B, Francis JH, Nathan PD. Metastatic disease from uveal melanoma: treatment options and future prospects. Br J Ophthalmol 2017; 101: 38-44. doi: doi: 10.1136/bjophthalmol-2016-309034
  2. Singh AD, Turell ME, Topham AK. Uveal melanoma: trends in incidence, treatment, and survival. Ophthalmology 2011; 118: 1881-5. doi: 10.1016/j.ophtha.2011.01.040
  3. Rietschel P, Panageas KS, Hanlon C, Patel A, Abramson DH, Chapman PB. Variates of survival in metastatic uveal melanoma. J Clin Oncol 2005; 23: 8076-80. doi: 10.1200/JCO.2005.02.6534
  4. Diener-West M, Reynolds SM, Agugliaro DJ, Caldwell R, Cumming K, Earle JD, et al. Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: Collaborative Ocular Melanoma Study Group Report No. 26. Arch Ophthalmol 2005; 123: 1639-43. doi: 10.1001/archopht.123.12.1639
  5. Nathan P, Cohen V, Coupland S, Curtis K, Damato B, Evans J, et al. Uveal Melanoma UK National Guidelines. Eur J Cancer 2015; 51: 2404-12. doi: 10.1016/j.ejca.2015.07.013
  6. Hassel JC, Piperno-Neumann S, Rutkowski P, Baurain J-F, Schlaak M, Butler MO, et al. Three-year overall survival with tebentafusp in metastatic uveal melanoma. N Engl J Med 2023; 389: 2256-66. doi: doi: 10.1056/NEJMoa2304753
  7. Buder K, Gesierich A, Gelbrich G, Goebeler M. Systemic treatment of metastatic uveal melanoma: review of literature and future perspectives. Cancer Med 2013; 2: 674-86. doi: 10.1002/cam4.133
  8. Schelhorn J, Richly H, Ruhlmann M, Lauenstein TC, Theysohn JM. A singlecenter experience in radioembolization as salvage therapy of hepatic metastases of uveal melanoma. Acta Radiol Open 2015; 4: 2047981615570417. doi: 10.1177/2047981615570417
  9. Heusner TA, Antoch G, Wittkowski-Sterczewski A, Ladd SC, Forsting M, Verhagen R, et al. Transarterial hepatic chemoperfusion of uveal melanoma metastases: survival and response to treatment. Rofo 2011; 183: 1151-60. doi: 10.1055/s-0031-1281743
  10. Gonsalves CF, Eschelman DJ, Adamo RD, Anne PR, Orloff MM, Terai M, et al. A prospective phase ii trial of radioembolization for treatment of uveal melanoma hepatic metastasis. Radiology 2019; 293: 223-31. doi: 10.1148/radiol.2019190199
  11. Leyvraz S, Piperno-Neumann S, Suciu S, Baurain JF, Zdzienicki M, Testori A, et al. Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021): a multicentric randomized trial. Ann Oncol 2014; 25: 742-6. doi: 10.1093/annonc/mdt585.
  12. Zimmermann A. Metastatic liver disease: associated liver lesions. In: Zimmermann A, editor. Tumors and tumor-like lesions of the hepatobiliary tract: general and surgical pathology. Cham: Springer International Publishing; 2017. p. 1973-87.
  13. Kromrey M, Ittermann T, Plodeck V, Seppelt D, Hoffmann R, Heiss P, et al. Reference values of liver volume in Caucasian population and factors influencing liver size. Eur J Radiol 2018; 106: 32-7. doi: 10.1016/j. ejrad.2018.07.005
  14. Wu C, Ning H, Liu M, Lin J, Luo S, Zhu W, et al. Spleen mediates a distinct hematopoietic progenitor response supporting tumor-promoting myelopoiesis. J Clin Invest 2018; 128: 3425-38. doi: 10.1172/JCI97973
  15. Xiao LS, Hu CY, Cui H, Li RN, Hong C, Li QM, et al. Splenomegaly in predicting the survival of patients with advanced primary liver cancer treated with immune checkpoint inhibitors. Cancer Med 2022; 11: 4880-8. doi: 10.1002/cam4.4818
  16. Fernández-Placencia R, Golse N, Cano L, Allard MA, Pittau G, Ciacio O, et al. Spleen volumetry and liver transient elastography: predictors of persistent posthepatectomy decompensation in patients with hepatocellular carcinoma. Surgery 2020; 168: 17-24. doi: 10.1016/j.surg.2020.02.009
  17. Prassopoulos P, Daskalogiannaki M, Raissaki M, Hatjidakis A, Gourtsoyiannis N. Determination of normal splenic volume on computed tomography in relation to age, gender and body habitus. Eur Radiol 1997; 7: 246-8. doi: 10.1007/s003300050145
  18. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-47. doi: 10.1016/j.ejca.2008.10.026
  19. Gragoudas ES, Egan KM, Seddon JM, Glynn RJ, Walsh SM, Finn SM, et al. Survival of patents with metastases from uveal melanoma. Ophthalmology 1991; 98: 383-90. doi: 10.1016/s0161-6420(91)32285-1
  20. Krantz BA, Dave N, Komatsubara KM, Marr BP, Carvajal RD. Uveal melanoma: epidemiology, etiology, and treatment of primary disease. Clin Ophthalmol 2017; 11: 279-89. doi: 10.2147/OPTH.S89591
  21. Kujala E, Mäkitie T, Kivelä T. Very long-term prognosis of patients with malignant uveal melanoma. Invest Ophthalmol Vis Sci 2003; 44: 4651-9. doi: 10.1167/iovs.03-0538
  22. Kuk D, Shoushtari AN, Barker CA, Panageas KS, Munhoz RR, Momtaz P, et al. Prognosis of mucosal, uveal, acral, nonacral cutaneous, and unknown primary melanoma from the time of first metastasis. Oncologist 2016; 21: 848-54. doi: 10.1634/theoncologist.2015-0522
  23. Müller L, Kloeckner R, Mähringer-Kunz A, Stoehr F, Düber C, Arnhold G, et al. Fully automated AI-based splenic segmentation for predicting survival and estimating the risk of hepatic decompensation in TACE patients with HCC. Eur Radiol 2022; 32: 6302-13. doi: 10.1007/s00330-022-08737-z
  24. Müller L, Gairing SJ, Kloeckner R, Foerster F, Weinmann A, Mittler J, et al. Baseline splenic volume outweighs immuno-modulated size changes with regard to survival outcome in patients with hepatocellular carcinoma under immunotherapy. Cancers (Basel) 2022; 14: 3574. doi: 10.3390/cancers14153574
  25. Wu WC, Chiou YY, Hung HH, Kao WY, Chou YH, Su CW, et al. Prognostic significance of computed tomography scan-derived splenic volume in hepatocellular carcinoma treated with radiofrequency ablation. J Clin Gastroenterol 2012; 46: 789-95. doi: 10.1097/MCG.0b013e31825ceeb5
  26. Galland L, Lecuelle J, Favier L, Fraisse C, Lagrange A, Kaderbhai C, et al. Splenic volume as a surrogate marker of immune checkpoint inhibitor efficacy in metastatic non small cell lung cancer. Cancers (Basel) 2021; 13: 3020. doi: 10.3390/cancers13123020
  27. Castagnoli F, Doran S, Lunn J, Minchom A, O’Brien M, Popat S, et al. Splenic volume as a predictor of treatment response in patients with non-small cell lung cancer receiving immunotherapy. PLoS One 2022; 17: e0270950. doi: 10.1371/journal.pone.0270950
  28. Feucht HE, Schneeberger H, Hillebrand G, Burkhardt K, Weiss M, Riethmüller G, et al. Capillary deposition of C4d complement fragment and early renal graft loss. Kidney Int 1993; 43: 1333-8. doi: 10.1038/ki.1993.187
  29. Theophilidou E, Waraich N, Raza T, Agarwal PK. Liver metastases, a rare cause of portal hypertension and stoma bleeding. Brief review of literature. Int J Surg Case Rep 2012; 3: 173-6. doi: 10.1016/j.ijscr.2011.11.008
DOI: https://doi.org/10.2478/raon-2025-0047 | Journal eISSN: 1581-3207 | Journal ISSN: 1318-2099
Language: English
Page range: 383 - 390
Submitted on: Mar 3, 2025
|
Accepted on: May 22, 2025
|
Published on: Sep 5, 2025
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2025 Hannah Luisa Steinberg-Vorhoff, Marcel Drews, Marcel Opitz, Natalie van Landeghem, Luca Salhöfer, Mathias Holtkamp, Yan Li, Johannes Haubold, Jens Siveke, Heike Richly, Michael Forsting, Benedikt Michael Schaarschmidt, Sebastian Zensen, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons Attribution 4.0 License.